


Annual Report to Shareholders 2002



Profiles Key technical personnel

Christine Cussen Chief Executive Officer

Christine Cussen, Eiffel's CEO, has worked in the pharmaceutical and healthcare industries for over 25 years. She has a background in biochemistry and was previously Managing Director for Zeneca Pharmaceuticals (now AstraZeneca) in Australia and New Zealand, a position she held for seven vears. Christine is a regular traveller with a minimum of six international trips each year marketing Eiffel Technologies to overseas biotech and pharmaceutical companies, Since joining Eiffel Technologies 18 months ago, Christine has negotiated five drug delivery agreements on Eiffel's behalf with international companies.

Bob Davis Consultant

Professor Bob Davis has been working on novel drug delivery systems for over 30 years and is a consultant to Eiffel Technologies. He is Professor of Pharmaceutical Sciences at the University of Nottingham in the United Kingdom and has published over 700 papers and co-edited seven books. He has also founded two pharmaceutical companies, DanBioSyst Ltd (now part of West Pharmaceutical Services in the UK) and Pharmaceutical Profiles Ltd. His area of expertise includes drug targeting, transmucosal delivery of pharmaceuticals, and oral and parenteral systems for controlled release of pharmaceuticals.

Professor Neil Foster Technical Director

Professor Neil Foster is the Technical Director of Eiffel Technologies. He has been the Professor of Chemical Engineering and Industrial Chemistry at the University of NSW since 1995 and has recently become a full-time employee of Eiffel. Neil is one of the leading researchers in the world in supercritical fluids with over 25 years experience in this field, and for the last 15 years has been investigating the application of SCF technology in pharmaceutical re-engineering.

Professor Colin Pouton Consultant

Colin is currently Professor of Pharmaceutical Biology at the Victorian College of Pharmacy and advises Eiffel on its Research & Development direction as a consultant. He has a wealth of pharmaceutical experience including over 25 years in academia. Colin has worked as a consultant to many of the major international pharmaceutical companies, most recently including Pfizer, AstraZeneca and GlaxoSmithKline. For six years he was European Editor-in-Chief of Advanced Drug Delivery Reviews and has an international reputation for his research in drug delivery and pharmaceutical biotechnology. He has specific expertise in physical pharmacy, drug delivery and targeting, gene delivery, and in improving the bioavailability of pharmaceutical compounds.

Hubert Regtop Research Director

Hub has recently become a full-time employee of Eiffel Technologies and has a background in biochemistry and microbiology with over 35 years experience as a researcher. In recent years his focus has been on the use of supercritical fluid technology for solubility and bioavailability enhancement of pharmaceutical products and the extraction of natural products using SCF techniques.

Rod Tomlinson Non-executive Director

Rod has a formal background in applied chemistry. In 1973 he founded Soltec Industries, which became a leading manufacturer of pharmaceuticals and sunscreen products in Australia. In 1988 Rod sold the manufacturing business to concentrate on Research & Development through Soltec Research, a company focused on the development of new drug and chemical delivery systems.

In 1996 Soltec Research was sold to FH Faulding and for three years Rod headed up the Company's global development and growth in drug delivery systems. In 2001 it was acquired by US company Connetics Corporation to gain access to its unique delivery systems and its valuable Research & Development work. Rod has since retired from full-time work although is continuing his part in creating an internationally renowned biotech industry in Australia through advising innovative local companies.